Sean Nolan, RA Session II
Crossover round? Check. Top team? Check. Taysha sails to an IPO with $100M initial ask
On the same day Novartis erased the AveXis brand from the company, the ex-AveXis crew says their new gene therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
